<DOC>
	<DOCNO>NCT02014584</DOCNO>
	<brief_summary>Treatment male pattern hair loss ( MPHL ) androgenetic alopecia ( AGA ) 5α-reductase inhibitor ( 5-ARIs ) associate sexual dysfunction include erectile dysfunction loss libido . This multicenter , randomize , double-blind , placebo-controlled , parallel-group study assess impact dutasteride treatment sexual function well subject satisfaction hair growth quality life men AGA . This study consist Screening Visit , 4-week Placebo Run-in Phase , Treatment Phase 48 week , subsequent Follow-up Visit 4 week . The treatment phase include 24 week double-blind , placebo control treatment 24 week open-label treatment dutasteride . An extended 6-month Follow-up Visit conduct individual change erectile function end treatment .</brief_summary>
	<brief_title>Sexual Function Men Receiving Dutasteride Androgenetic Alopecia</brief_title>
	<detailed_description />
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<criteria>Subject agree participate study sign date informed consent form prior initiation studyrelated activity . AGA classify utilizing NorwoodHamilton classification . Men 18 50 year old , inclusively . Fluent literate local language ability comprehend record information International Index Erectile Function , Hair Growth Satisfaction Scale , DLQI questionnaires . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 2x upper limit normal ( ULN ) ; alkaline phosphatase bilirubin ≤1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Have stable heterosexual relationship last 6 month prior screen expect maintain relationship throughout study . Must sexually active : man consider sexually active engage sexual intercourse ( least ) 4 week prior screen . Men female partner childbearing potential must agree avoid exposure partner semen use condom . Use condom must 2 week prior administration first dose study treatment least 5 halflives drug ( 45 day ) plus 3 month ( i.e. , total 4.5 month ) allow clearance residual drug semen last dose study treatment . Willing comply study requirement . Current preexist sexual dysfunction determine : History erectile dysfunction define consistent inability achieve maintain erection sufficient permit satisfactory sexual intercourse . Score ≤25 erectile function domain ( IIEFEF ) IIEF screen baseline visit . Evidence hypogonadism . Have communicable skin sexuallytransmitted disease , rash lesion penis surround area ( report subject evaluate investigator ) . Serum prostatespecific antigen ( PSA ) &gt; 2.0 ng/mL screening . Serum creatinine &gt; 1.5xULN screening . Unstable liver disease ( chronic stable hepatitis B C acceptable subject otherwise meet entry criterion ) . History malignancy ( include prostate cancer ) within past 5 year , except basal cell squamous cell carcinoma skin . History prostate cancer age 50 year first degree relative . History breast cancer clinical breast examination suggestive malignancy . Any unstable , serious coexist medical condition ( ) include , limited , myocardial infarction , coronary bypass surgery , unstable angina , cardiac arrhythmia , clinically evident congestive heart failure , cerebrovascular accident within 6 month prior screen ; uncontrolled diabetes peptic ulcer disease uncontrolled medical management . History current evidence serious and/or unstable preexist medical psychiatric disorder , condition could , opinion investigator medical monitor , interfere subject 's safety , obtain informed consent , compliance study procedures.Note : investigator may consult GSK medical monitor condition could interfere subject 's safety . Global scalp hair thin , include occipital area . Scarring scalp , include prior hair transplant scalp reduction , condition disease scalp hair , include disease hair shaft ( e.g. , tinea infection , nonandrogeneticcause alopecia , psoriatic dermatitis psoriatic lesion , uncontrolled seborrheic dermatitis ) . History hair transplantation time correct AGA use hair weave within 6 month prior screen . History evidence hair loss AGA ( e.g. , due autoimmune , endocrine , mechanical infectious process , secondary scalp dermatological disorder ) . Use cosmetic product aim improve correct sign hair loss ( e.g. , scalp preparation claim aim improved hair growth ) within 2 week prior screen . Use light laser treatment scalp ( e.g. , light emit diode [ LED ] lamp ) within 3 month prior screen . Hypersensitivity 5alpha reductase inhibitor ( 5ARI ) component excipients drug chemically relate study treatment . Use dutasteride within 10 month prior screen use finasteride within 6 month prior screen . Previous use systemic cytotoxic agent . Use glucocorticoid ( inhaled glucocorticoid allow ; topical corticosteroid allow provide used scalp ) within 3 month prior screen . Use follow prior Baseline ( within 1 week topical product ; within 1 week 5 halflives , whichever longer , systemic treatment ) : Phosphodiesterase type 5 ( PDE5 ) inhibitor ( e.g. , sildenafil , tadalafil , vardenafil ) ; Minoxidil ( oral topical ) ; Carpronium chloride ; Systemic drug antiandrogenic property ( e.g. , cyproterone acetate , spironolactone , ketoconazole , flutamide , bicalutamide ) ; Topical systemic estrogen progesterone ; Drugs potentially cause hypertrichosis ( e.g. , cyclosporine , diazoxide , phenytoin , psoralens ) ; Drugs potentially cause hypertrichosis telogen effluvium ( e.g. , valproic acid ) ; Anabolic steroid ; Participation study investigational market drug ( within 5 half life drug ) device may affect hair growth sexual function prior screen study . Note : Subject must participate drug device study course study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>quality life</keyword>
	<keyword>safety</keyword>
	<keyword>sexual function</keyword>
	<keyword>male pattern hair loss ( MPHL )</keyword>
	<keyword>Androgenic alopecia ( AGA )</keyword>
	<keyword>dutasteride</keyword>
	<keyword>satisfaction hair growth</keyword>
</DOC>